Novavax, Inc. is a biotechnology company specializing in recombinant protein-based nanoparticle vaccines and its proprietary Matrix-M adjuvant. Its primary commercial product is the COVID-19 Vaccine (Nuvaxovid), authorized in the U.S., EU, and other countries. Novavax partners with Sanofi for commercialization of Nuvaxovid, licenses Matrix-M adjuvant to partners including for the R21/Matrix-M malaria vaccine, and is advancing early-stage pipeline programs in infectious and other diseases.
Q2 FY2026 — expected 2026-08-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001000694-26-000007 | EDGAR | 92K words |
| 2025-02-27 | 2024-12-31 | 0001000694-25-000004 | EDGAR | 93K words |
| 2024-02-28 | 2023-12-31 | 0001000694-24-000007 | EDGAR | 95K words |
| 2023-02-28 | 2022-12-31 | 0001000694-23-000005 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001000694-22-000004 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001000694-21-000004 | EDGAR | — |
| 2020-03-11 | 2019-12-31 | 0001104659-20-031944 | EDGAR | — |
| 2019-03-18 | 2018-12-31 | 0001144204-19-014640 | EDGAR | — |
| 2018-03-14 | 2017-12-31 | 0001144204-18-014686 | EDGAR | — |
| 2017-02-27 | 2016-12-31 | 0001144204-17-011334 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001000694-26-000018 | EDGAR | 26K words |
| 2025-11-06 | 2025-09-30 | 0001000694-25-000046 | EDGAR | 32K words |
| 2025-08-06 | 2025-06-30 | 0001000694-25-000029 | EDGAR | 34K words |
| 2025-05-08 | 2025-03-31 | 0001000694-25-000021 | EDGAR | 28K words |
| 2024-11-12 | 2024-09-30 | 0001000694-24-000043 | EDGAR | 31K words |
| 2024-08-08 | 2024-06-30 | 0001000694-24-000035 | EDGAR | 66K words |
| 2024-05-10 | 2024-03-31 | 0001000694-24-000031 | EDGAR | 29K words |
| 2023-11-09 | 2023-09-30 | 0001000694-23-000055 | EDGAR | 35K words |
| 2023-08-08 | 2023-06-30 | 0001000694-23-000047 | EDGAR | 34K words |
| 2023-05-09 | 2023-03-31 | 0001000694-23-000040 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001000694-22-000024 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001000694-22-000016 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001000694-26-000019 | EDGAR | 1K words |
| 2026-02-26 | 0001000694-26-000011 | EDGAR | 5K words |
| 2026-01-20 | 0001104659-26-004785 | EDGAR | 2K words |
| 2026-01-12 | 0001104659-26-002725 | EDGAR | 3K words |
| 2025-11-06 | 0001000694-25-000048 | EDGAR | 4K words |
| 2025-11-04 | 0001104659-25-105818 | EDGAR | 1K words |
| 2025-10-22 | 0001104659-25-101390 | EDGAR | 2K words |
| 2025-10-07 | 0001104659-25-097317 | EDGAR | 1K words |
| 2025-08-27 | 0001104659-25-084053 | EDGAR | 59K words |
| 2025-08-27 | 0001104659-25-084049 | EDGAR | 1K words |
317 total filings indexed. 285 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001000694 |
| Ticker | NVAX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Headquarters | Gaithersburg, Maryland |
| Website | https://www.novavax.com |
| Listed | 1995-12-05 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NVAX (~200 tokens, structured JSON with cryptographic provenance)